Printer Friendly

RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN SHOW LONG-TERM EFFECTS

 SEATTLE, Nov. 10 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE), the leader in the field of immunoadsorption, announced today long-term, positive results from the treatment of eleven refractory rheumatoid arthritis patients with the company's PROSORBA(R) column. Seven of the 11 patients treated showed a sustained clinical response to PROSORBA column treatment one year after starting treatments. Rheumatoid arthritis affects over two million patients in the United States.
 Drs. Craig Wiesenhutter and Juergen Bertram, who supervised the long-term independent trial at the Coeur d'Alene Arthritis Clinic and North Idaho Cancer Center in Coeur d'Alene, Idaho, presented these findings at the 1993 Annual Meeting of the American College of Rheumatology in San Antonio, Texas today.
 The 11 patients participating in the test had been treated with non-steroidal anti-inflammatory drugs without success for an average period of 12.4 years. Patients were treated with the PROSORBA column twice a week for three weeks and then once a week for an additional nine weeks for a total of 15 treatments. Three of the patients were retreated during the one-year follow-up an average of eight times. Of the 11 patients, two had complete remission of their disease, eight had significant reduction in their pain index, number of painful joints, swelling index, and the number of swollen joints. Patients were all evaluated by the "Criteria for Clinical Remission in Rheumatoid Arthritis" used by the American Rheumatism Association (ARA). At one year there was significant improvement in every clinical parameter. All patients experienced flu-like symptoms following the treatment which lasted for 1 to 24 hours.
 A year ago, IMRE' Corporation initiated an FDA-approved, multi- center study at three major U.S. medical institutions to repeat the results of the independent study. Results of IMRE's clinical trial have confirmed the report of one year ago by Drs. Wiesenhutter and Bertram. Based on the recommendation of the clinicians who participated in IMRE's multi-center study and the collection of supporting data on 14 patients, IMRE asked the FDA this week for permission to expand its multi-center clinical trial in rheumatoid arthritis, as soon as possible.
 "The results from these two clinical studies encourage us to move as quickly as possible into the next stage of trials," said Dr. Frank R. Jones, chairman and chief executive officer of IMRE. "Rheumatoid arthritis is the largest patient population for which this treatment has been tested."
 The PROSORBA column was developed by IMRE scientists. It is a disposable, single-use cylindrical canister about three inches in diameter and three inches in height. The column contains a patented matrix comprised of molecules called protein A bound to granules of silica. This matrix removes immune suppressor molecules from a patient's blood plasma. Following removal of the immune suppressor molecules, the body's immune system acts more normally and can combat the disease. In the two-hour procedure, a patient's plasma is separated from the blood cells, passed through the column, recombined with the cells, and re-infused into the same patient.
 IMRE Corporation is a medical products company that is the leader in the field of immunoadsorption treatments. The company's first product, the PROSORBA column, has been marketing approved by the Food and Drug Administration and is sold for the treatment of immune thrombocytopenic purpura (ITP), an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases, and certain cancers.
 -0- 11/10/93
 /CONTACT: Lois Yoshida of IMRE Corporation, 206-298-9400/
 (IMRE)


CO: IMRE Corporation ST: Washington IN: MTC SU:

LD-MP -- NY003 -- 2581 11/10/93 08:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1993
Words:584
Previous Article:AIR METHODS ANNOUNCES 22ND AIR MEDICAL CONTRACT AT WESTERGAARD GROWTH STOCK CONFERENCE IN NEW YORK
Next Article:MASCOTT CORPORATION SUSPENSION OF OPERATIONS OF MARKERS ITALIAN GRILLE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters